Copyright: ©Author(s) 2026.
World J Hepatol. Jul 27, 2026; 18(7): 121661
Published online Jul 27, 2026. doi: 10.4254/wjh.121661
Published online Jul 27, 2026. doi: 10.4254/wjh.121661
Table 3 Comparison of laboratory test results
| Variable | Total (n = 122) | Stage F1 (n = 21) | Stage F2 (n = 86) | Stage F3 (n = 15) | P value |
| ALT (U/L) | 85 (53.4, 141.7) | 70.2 (39, 121) | 85.5 (55.7, 143.5) | 93.2 (59, 158.3) | 0.351 |
| AST (U/L) | 49.5 (36.2, 76) | 47 (29.1, 66.9)a | 49 (36.2, 71.5) | 80 (43.9, 100.4) | 0.031 |
| ALP (U/L) | 76.1 (63, 89.3) | 71(58, 89.6) | 77.3 (63.9, 88) | 86 (54.9, 98.4) | 0.498 |
| GGT (U/L) | 70.4 (46.8, 105.2) | 72 (39, 115.2) | 70.4 (46, 106.1) | 70 (58, 97.5) | 0.9 |
| ALB (g/L) | 47.6 (45.5, 49.8) | 47.5 (44.7, 49) | 47.8 (46, 50.3)b | 45.5 (42.2, 47.9) | 0.008 |
| TBA (µmol/L) | 3.2 (2, 5.3) | 3 (2, 6) | 3 (2, 5) | 4 (3, 6) | 0.367 |
| TP (g/L) | 75.5 ± 5.1 | 75.2 ± 5.9 | 75.9 ± 4.7 | 73.2 ± 5.9 | 0.163 |
| TBIL (µmol/L) | 14 (11.6, 17.4) | 14 (10.5, 18.7) | 13.4 (11.5, 17.2) | 15.2 (13.1, 18.8) | 0.241 |
| DBIL (µmol/L) | 2.9 (1.9, 4.5) | 2.4 (1.7, 6.2) | 3 (1.7, 4.4) | 2.4 (1.9, 4.7) | 0.972 |
| IBIL (μmol/L) | 11 (8.8, 13.2) | 11.1 (7.6, 14.2) | 10.8 (8.8, 12.5) | 12.8 (10, 13.5) | 0.251 |
| BUN (g/L) | 4.5 (3.9, 5.2) | 6.6 (3.9, 5) | 4.5 (3.8, 5.2) | 4.9 (4.2, 5.9) | 0.195 |
| CRE (µmol/L) | 62.9 ± 14.4 | 62.6 ± 13.8 | 62.6 ± 14.0 | 65.5 ± 18.3 | 0.766 |
| UA (µmol/L) | 375 (334.4, 466) | 379 (346.8, 490.5) | 375 (320.9, 462.6) | 374 (363, 491) | 0.646 |
| eGFR (mL/minute/1.73 m2) | 110.8 ± 13.7 | 110.6 ± 14.3 | 113.3 ± 12.1c | 102.5 ± 18.6 | 0.036 |
| FPG (mmol/L) | 5.9 (5.5, 6.7) | 5.7 (5.4, 6.2) | 6 (5.5, 6.8) | 6.2 (5.3, 6.9) | 0.169 |
| TC (mmol/L) | 5.4 ± 1.2 | 5.2 ± 1.3 | 5.4 ± 1.2 | 6.0 ± 1.3 | 0.159 |
| TG (mmol/L) | 1.8 (1.4, 2.5) | 1.9 (1.7, 3) | 1.8 (1.3, 2.4) | 1.9 (1.5, 2.5) | 0.231 |
| HDL (mmol/L) | 1.3 ± 0.3 | 1.3 ± 0.3 | 1.3 ± 0.3 | 1.3 ± 0.2 | 0.599 |
| LDL (mmol/L) | 3.3 ± 1 | 2.9 ± 0.9d | 3.3 ± 0.9 | 3.8 ± 1 | 0.034 |
| Glo (%) | 15.3 (13.8, 16.8) | 15.7 (13.8, 16.5) | 15.1 (13.9, 17.1) | 15.2 (12.8, 17.4) | 0.942 |
| IgG (g/L) | 11.95 (10.31, 14.14) | 11.8 (9.44, 14.07) | 12.33 (10.68, 14.28) | 11.2 (10, 13.45) | 0.29 |
| IgM (g/L) | 0.95 (0.69, 1.19) | 0.97 (0.73, 1.18) | 0.9 (0.66, 1.17) | 1.13 (0.73, 1.72) | 0.267 |
| IgA (g/L) | 2.43 (1.81, 3.21) | 2.32 (1.83, 3.11) | 2.5 (1.82, 3.18) | 2.23 (1.54, 3.49) | 0.949 |
| WBC (109/L) | 6.3 ± 1.5 | 6.3 ± 1.6 | 6.3 ± 1.5 | 6.5 ± 1.2 | 0.856 |
| RBC (1012/L) | 4.91 (4.59, 5.29) | 4.84 (4.47, 5.12) | 4.95 (4.59, 5.36) | 4.88 (4.56, 5.29) | 0.351 |
| Hb (g/L) | 146 ± 14.6 | 144 ± 10.7 | 146.9 ± 15.7 | 145.9 ± 12.4 | 0.72 |
| PLT (109/L) | 248 ± 65 | 247.6 ± 78.6 | 252.2 ± 66.0 | 224.7 ± 31.1 | 0.309 |
| PT (s) | 11.1 (10.6, 12.53) | 12.1 (10.4, 12.95) | 11.1 (10.6, 11.95) | 11.6 (10.8, 13) | 0.272 |
- Citation: Pan PY, Zheng WW, Guo YQ, Liu YG, Zhang XJ, Wu YY, Li JZ, Qi JG, Wang CY. Clinicopathological characteristics and risk factors in nonalcoholic steatohepatitis patients with different stages of liver fibrosis. World J Hepatol 2026; 18(7): 121661
- URL: https://www.wjgnet.com/1948-5182/full/v18/i7/121661.htm
- DOI: https://dx.doi.org/10.4254/wjh.121661